Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease
Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA ...
Healio20h
‘Pivotal moment’: Uplizna becomes first FDA-approved treatment for IgG4-related disease
The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only approved treatment ...
Pharmabiz7h
US FDA approves Amgen’s Uplizna to treat IgG4-related disease
US FDA approves Amgen’s Uplizna to treat IgG4-related disease: Thousand Oaks, California Saturday, April 5, 2025, 11:00 Hrs [IST] Amgen announced that the US Food and Drug Admin ...
Medscape17h
FDA Approves First and Only Therapy for IgG4-RD
Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 antibody positive, in 2020. It has also been designated as an ...
MPR19h
Uplizna Approved to Treat Immunoglobulin G4-Related Disease
The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease (IgG4-RD) in adult patients.
Fierce Pharma21h
Amgen wins key rare disease nod for Uplizna, checking off one goal in expansion push
With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...
The Pharma Letter21h
Amgen’s Uplizna first FDA-approved drug for Ig4A-RD
The US Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon) as the first and only treatment for adults ...
Zacks Investment Research on MSN19h
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication
Amgen AMGN announced that the FDA has approved its rare disease drug Uplizna (inebilizumab) for a new indication. The ...
Texas Court Rejects J&J’s Bankruptcy Attempt to End Talc Suits
A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the third time. In September, J&J, via a subsidiary called Red River Talc, filed ...
Asianet Newsable on MSN22h
Amgen Stock Edges Higher After Uplizna Becomes First FDA-Approved Treatment For Immune-Mediated Disorder – Retail Gets More Bullish
Shares of medicine manufacturer Amgen Inc (AMGN) are in the spotlight on Friday after it announced that the U.S. Food and ...
Contract Pharma22h
Amgen’s UPLINZA Approved by FDA as Treatment for IgG4-RD
The U.S. Food and Drug Administration (FDA) has approved Amgen’s UPLIZNA as the first and only treatment for adults living ...
Guggenheim Reiterates Buy Rating for Compass Therapeutics (NASDAQ:CMPX)
Guggenheim restated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report issued on Wednesday morning,Benzinga reports. They currently have a $12.00 target price ...